Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Biomed Res Int ; 2015: 167323, 2015.
Article in English | MEDLINE | ID: mdl-26120579

ABSTRACT

CK2 is a protein kinase distributed in different compartments of Leishmania braziliensis: an externally oriented ecto-CK2, an intracellular CK2, and a secreted CK2. This latter form is constitutively secreted from the parasite (CsCK2), but such secretion may be highly enhanced by the association of specific molecules, including enzyme substrates, which lead to a higher enzymatic activity, called inductively secreted CK2 (IsCK2). Here, we examined the influence of secreted CK2 (sCK2) activity on the infectivity of a virulent L. braziliensis strain. The virulent strain presented 121-fold higher total CK2 activity than those found in an avirulent strain. The use of specific CK2 inhibitors (TBB, DRB, or heparin) inhibited virulent parasite growth, whereas no effect was observed in the avirulent parasites. When these inhibitors were added to the interaction assays between the virulent L. braziliensis strain and macrophages, association index was drastically inhibited. Polyamines enhanced sCK2 activity and increased the association index between parasites and macrophages. Finally, sCK2 and the supernatant of the virulent strain increased the association index between the avirulent strain and macrophages, which was inhibited by TBB. Thus, the kinase enzyme CK2 seems to be important to invasion mechanisms of L. braziliensis.


Subject(s)
Casein Kinase II/immunology , Leishmania braziliensis/enzymology , Leishmaniasis, Cutaneous/immunology , Animals , Casein Kinase II/chemistry , Casein Kinase II/metabolism , Humans , Leishmania braziliensis/immunology , Leishmania braziliensis/pathogenicity , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Cutaneous/pathology , Macrophages/immunology , Macrophages/parasitology , Mice , Mice, Inbred BALB C
2.
Biomed Res Int ; 2015: 324915, 2015.
Article in English | MEDLINE | ID: mdl-26090399

ABSTRACT

The intracellular protozoa Leishmania spp. and Trypanosoma cruzi and the causative agents of Leishmaniasis and Chagas disease, respectively, belong to the Trypanosomatidae family. Together, these two neglected tropical diseases affect approximately 25 million people worldwide. Whether the host can control the infection or develops disease depends on the complex interaction between parasite and host. Parasite surface and secreted molecules are involved in triggering specific signaling pathways essential for parasite entry and intracellular survival. The recognition of the parasite antigens by host immune cells generates a specific immune response. Leishmania spp. and T. cruzi have a multifaceted repertoire of strategies to evade or subvert the immune system by interfering with a range of signal transduction pathways in host cells, which causes the inhibition of the protective response and contributes to their persistence in the host. The current therapeutic strategies in leishmaniasis and trypanosomiasis are very limited. Efficacy is variable, toxicity is high, and the emergence of resistance is increasingly common. In this review, we discuss the molecular basis of the host-parasite interaction of Leishmania and Trypanosoma cruzi infection and their mechanisms of subverting the immune response and how this knowledge can be used as a tool for the development of new drugs.


Subject(s)
Chagas Disease/immunology , Host-Parasite Interactions/immunology , Leishmaniasis/immunology , Trypanosoma cruzi/immunology , Antigens/immunology , Chagas Disease/epidemiology , Chagas Disease/parasitology , Humans , Leishmania/immunology , Leishmania/pathogenicity , Leishmaniasis/epidemiology , Leishmaniasis/parasitology , Trypanosoma cruzi/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL
...